patent/MY-121604-A

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MY-121604-A

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
classificationIPCAdditional	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D411-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H5-10
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18
filingDate	1996-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c1cd7cb165358563893118040ee866c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbc197b0d8d6023921be678a5b24fc33
publicationDate	2006-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	MY-121604-A
titleOfInvention	Combination therapy for hiv infection using the hiv protease inhibitor indinavir and the reverse transcriptase inhibitor 3tc together with azt
abstract	THE COMBINATION OF THE HIV PROTEASE INHIBITOR COMPOUND J, 3 TC, AND, OPTIONALLY AZT, DDI, OR DDC, IS USEFUL IN THE INHIBITION OF HIV PROTEASE, THE INHIBITION OF HIV REVERSE TRANSCRIPTASE, THE PREVENTION OR TREATMENT OF INFECTION BY HIV AND THE TREATMENT OF AIDS, EITHER AS COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS, PHARMACEUTICAL COMPOSITION INGREDIENTS, WHETHER OR NOT IN COMBINATION WITH OTHER ANTIVIRALS, IMMUNOMODULATORS, ANTIBIOTICS OR VACCINES.
priorityDate	1995-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5362440 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID100862683 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419502998

Total number of triples: 35.